Cardiovascular calcification in patients with chronic renal failure: Are we on target with this risk factor?  by Mccullough, Peter A. & Soman, Sandeep
Kidney International, Vol. 66, Supplement 90 (2004), pp. S18–S24
Cardiovascular calcification in patients with chronic renal
failure: Are we on target with this risk factor?
PETER A. MCCULLOUGH and SANDEEP SOMAN
Divisions of Cardiology, Nutrition and Preventive Medicine, Department of Medicine, William Beaumont Hospital, Royal Oak,
Michigan; and Division of Nephrology and Hypertension, Department of Medicine, Veterans Affairs Medical Center, Fargo,
North Dakota
Cardiovascular calcification in patients with chronic renal fail-
ure: Are we on target with this risk factor? End-stage renal
disease (ESRD) is comprised of conditions associated with
metabolic disorders associated with soft tissue and coronary
artery calcification (CAC). The most consistent determinants
of CAC in these patients are extent and duration of renal dys-
function and older age. The majority of published studies have
not found a causal relationship between measures of calcium-
phosphorus balance and CAC. When taken into consideration,
the lipid profile [primarily low high-density lipoprotein choles-
terol, elevated triglycerides, elevated low-density lipoprotein
(LDL-C), and elevated total cholesterol] are important factors
in the calcification process. Recent data seems to indicate that
CAC is regulated both positively and negatively by a wide va-
riety of mechanisms affecting patients with renal disease. The
progression of CAC can be reduced from a 25% to 30% to 0% to
6% annual increase with LDL-C reduction caused by statins or
possibly sevelamer. It is currently unclear whether the calcium-
phosphorus balance and its related treatments are involved in
CAC progression in ESRD patients. Further research into the
determinants and potential treatments for CAC in association
with ESRD is warranted.
CALCIUM DEPOSITION IN ATHEROSCLEROSIS
Atherosclerotic calcification begins as early as the sec-
ond decade of life, just after fatty streak formation [1].
Coronary artery lesions of young adults have revealed
small aggregates of crystalline calcium within the lipid
core of a plaque [1]. Calcium phosphate (hydroxyap-
atite, Ca3[-PO4]2−xCa[OH]2), which contains 40% cal-
cium by weight, precipitates in diseased coronary arteries
by a mechanism similar to that found in osteogenesis and
remodeling [2]. Hydroxyapatite, the predominant crys-
talline form in calcium deposits, is formed primarily in
vesicles that pinch off from arterial wall cells, analogous to
the way matrix vesicles pinch off from chondrocytes in de-
veloping bone [3, 4]. It has been postulated that vesicles,
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derived from apoptotic foam and smooth muscle cell de-
bris and contained within extracellular matrix, may also
serve as the sites of small calcium deposits. A very close
spatial association between cholesterol deposits and hy-
droxyapatite has also been demonstrated [5]. The exact
mechanism and process of calcification within the arterial
wall is not yet completely understood.
Coronary artery calcification (CAC) seems to occur
exclusively in atherosclerotic arteries, and is absent in
normal vessel wall [6]. Overall, present findings lend cre-
dence to the idea that atherosclerotic calcification is not
merely passive adsorption but instead is an organized,
regulated process similar in many respects to bone forma-
tion. Thus, the finding of calcification on human imaging
studies implies the anatomic presence of atherosclerosis.
However, it is now understood that the presence of
atherosclerosis is a necessary but not sufficient condi-
tion to results in a coronary artery disease (CAD) event.
Plaque rupture, exposure of the lipid-rich core to the
blood pool, thrombosis, and occasional complete occlu-
sion of the vessel, and downstream embolization of the
platelet-thrombin complexes are believed to be the se-
quence in which an acute coronary syndrome occurs.
Hence, it makes sense that CAC (measured by nonin-
vasive imaging methods) indicates that the substrate for
an event is present; however, other risk factors including
dyslipidemia, hypertension, diabetes, smoking, obesity,
physical inactivity, and systemic inflammatory factors all
still contribute to the risk of a future CAD event [7–13].
Coronary artery calcification in patients without
kidney disease
Considerable interest exists in identifying and quanti-
fying CAC as a marker for atherosclerotic CAD. In pa-
tients without renal insufficiency, a high coronary calcium
score (>100) on electron beam computed tomography
(EBCT) carries a relative risk for future CAD events of
approximately 10 compared to those would have a score
<100 [1, 2] (see Fig. 1). Furthermore, it appears that a
sufficiently high CAC score (>300) modifies the risk for
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Fig. 1. Relative risk for cardiovascular disease (CVD) events in the St.
Francis Heart Study of 5585 subjects without kidney disease, who un-
derwent electron beam computed tomography (EBCT) calcium scoring
and were followed for 4.3 years. Data from reference [50].
future CAD events above that predicted by the conven-
tional Framingham risk prediction [14]. The absence of
detectable CAC is associated with a low future event rate;
however, this rate is not zero. In the South Bay Heart
Watch Study, 14/316 (4.4%) subjects with a CAC score
of zero went on to suffer nonfatal myocardial infarction
or cardiac death over a median seven years after EBCT
[14].
Currently, EBCT is not supported by the guidelines
for routine screening or CAD risk prediction. A meta-
analysis published in 2001 from nine studies with 1662
subjects found the pooled sensitivity for EBCT was
92.3% and specificity was 51.2% for obstructive coro-
nary disease [15]. However, it is known that the higher
the coronary calcium score, the greater the probably of
obstructive coronary disease.
CAC, once identified, appears to progress at a mea-
surable annual rate of approximately 30% in CAC vol-
ume on annual EBCT examinations [16, 17]. The pro-
gression of CAC has been linked to cigarette smoking,
poor glycemic control in diabetes, and probably could be
linked to the other conventional CAD risk factors [16,
17]. Several nonrandomized studies using treatment with
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase inhibitors (statins) have demonstrated attenu-
ation of progression in CAC associated with low-density
lipoprotein cholesterol (LDL-C) reduction (see Fig. 2)
[18, 19]. Some patients in these studies have had arrest or
reversal in the calcification process; however, the deter-
minants beyond LDL-C reduction of this reversal process
are not completely understood (see Fig. 3) [18]. In addi-
−40
−20
0
20
40
60
80
100
%
 A
nn
ua
liz
ed
 c
ha
ng
e
EBT 1 - EBT 2 EBT 2 - EBT 3
Fig. 2. The attenuation of progression of coronary calcification that can
be achieved with statin therapy. EBT, electron beam tomography. EBT
1–2 is untreated, EBT 2–3 is the annual change on statin therapy with
an LDL-C <100 mg/dL. Reproduced with permission from reference
[18].
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Fig. 3. The natural history of an atherosclerotic plaque. In the ad-
vanced stages, the plaque is thought to be lipid poor, heavily calcified,
and potentially stable with lower rates of coronary artery disease (CAD)
events than earlier in life. Reproduced with permission from reference
[26].
tion, in at least one study using a calcium channel blocker
in treating hypertension, there was mild attenuation of
the progression of calcification by EBCT [20].
So the key concepts on CAC in patients without kid-
ney disease are (1) the presence of CAC identifies the
presence of atherosclerotic plaque which is not neces-
sarily obstructive, (2) the presence of CAC significantly
increases the relative risk of a future CAD event, (3) the
absence of CAC does not preclude the future formation
and rupture of plaque resulting in a CAD event; how-
ever, this risk is low (<5%) over seven years, and (4)
CAC, when measured on serial tests, appears to progress
from year to year, and this progression can be attenuated,
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but not halted or reversed, with statins and perhaps blood
pressure control and other risk factor modification.
Coronary artery calcification in patients with end-stage
renal disease
Patients with end-stage renal disease (ESRD) requir-
ing dialysis are the highest risk states for incident and
accelerated cardiovascular disease [21, 22]. Prior stud-
ies have shown that vascular calcification is enhanced
in ESRD, and recent data using EBCT has shown a
modest relationship between calcium scores and calcium-
phosphorus ion product [23–24]. An attractive hypothe-
sis accounting for these observations is that patients with
ESRD have abnormal and accelerated vascular calcifica-
tion [25–27]. However, it is currently unknown whether
the calcification in these patients is a poor prognostic fac-
tor, or related to the pathogenesis of CAD in a favorable
or unfavorable way.
Vascular calcification potentially is a different process
in those patients with ESRD compared to those with nor-
mal renal function. The calcification in ESRD is thought
to occur at two sites in the vessel wall: in the media
where it is known as Mo¨nckeberg’s sclerosis (occurs ini-
tially in the media of the vessel, usually at the inter-
nal elastic lamina, and is not associated with lipid-laden
macrophages and intimal hyperplasia), and in the intima
(typically found in large vessel disease and coronary ar-
teries, and associated with lipid-laden macrophages and
intimal hyperplasia), where it is invariably associated with
atherosclerosis. Cell biology studies suggest CAC is an
active process analogous to bone formation, given that
several genes expressed by calcifying vascular smooth
muscle cells are also expressed by osteoblasts [3, 4]. Bone
matrix proteins, including osteocalcin, matrix Gla pro-
tein, and osteopontin have been found in calcified arterial
vessels. Interestingly, matrix Gla protein and osteopontin
appear to act as inhibiting factors to the CAC process [28].
A matrix gamma-carboxyglutamic acid protein (MGP)
knockout mouse, which exhibits extensive and lethal cal-
cification of the media of all elastic arteries, suggests Gla-
containing proteins play a role in response to the CAC
process. In vitro studies have shown that although normal
vascular smooth muscle cells constitutively express MGP
messenger RNA, it is substantially up-regulated in cells
adjacent to both medial and intimal calcification occur-
ring in the extracellular space [29].
Primary vascular smooth muscle cells (VSMCs) from
explants of medial tissue of both normal and diseased
arteries transform into phenotypically distinct cells capa-
ble of calcification in vitro [2]. These modified VSMCs
facilitate mineralization in vitro by forming nodules
similar to those produced by osteoblasts, producing
bone-associated proteins and forming matrix vesicles. A
variety of stimuli have been shown to induce or modulate
phenotypic transformation of VSMCs to osteoblast-like
cells with subsequent mineralization in vitro, including
phosphorus, oxidized LDL-C, calcitriol, parathyroid hor-
mone, and parathyroid hormone–related peptide [31, 32].
In vitro data with modified VSMCs (which arise from
the same pluripotent cell as does the osteoblast) support
that phosphorus can lead to calcification, and that phos-
phorus can induce Cbfa1 (a transcription factor critical
for osteoblast differentiation and the expression of the
bone matrix proteins osteopontin, osteocalcin, and type
I collagen) and the expression of bone matrix proteins.
Hyperphosphatemia, a laboratory abnormality common
in ESRD patients, therefore could represent an important
stimulus by which uremia predisposes to excessive vascu-
lar calcification [33–35]. The effect of calcium loading and
of phosphate binding with changes in the serum levels of
calcium and phosphorus on the basic process of vascular
calcification is unknown. As reviewed below, the clinical
studies in ESRD suggest the process is driven much more
by the age, length of time on dialysis, and lipid status [38].
While it may appear that phosphorus level and mortal-
ity are related, the causal pathway is poorly understood,
though some recently postulated mechanisms are listed
below. It is also not clear that these processes involve
CAC [30].
It has been shown that heavy calcification may be as-
sociated with lower LDL-C and improved outcomes af-
ter percutaneous coronary intervention in patients with
ESRD [36–37]. However, knowledge of the determinants
of CAC and its related outcomes in chronic kidney dis-
ease (CKD) and ESRD has been limited by the routine
exclusion of CKD and ESRD from most of the large ran-
domized trials and epidemiologic studies. In a systematic
review of the literature concerning CKD and ESRD
(1982 to 2002, N = 2919), imaging methods used for
vascular calcification included: x-ray 13/31 (43%), com-
puted tomography 10/31 (30%), ultrasound 5/31 (17%),
and 3/31 (10%) other methods [38].
The 31 studies included in the review were split on ei-
ther finding or not finding significance of serum calcium
(Ca), serum phosphorus (PO4), calcium-phosphorus
product (CPP), parathyroid hormone (PTH), or treat-
ments for calcium-phosphorus (Ca-PO4) balance includ-
ing phosphate binders, calcium, and vitamin D analogues
(VDA), in relation to CAC [38]. Table 1 contains six stud-
ies concerning vascular calcification in ESRD. In general,
CAC was related to older age, length of time on dialysis
therapy or dialysis vintage (DV), osteopontin levels (one
study), and dyslipidemia. In the study by Goodman et al,
the majority (13/14) of patients with ESRD and CAC had
previously undergone renal transplantation, which, along
with DV, appeared to be major determinants of calcifica-
tion [24]. Those with the longest DV times had undergone
transplantation at some time point during their course
of ESRD, and the cumulative durations of transplant
McCullough and Soman: Cardiovascular calcification in chronic renal failure S-21
Ta
bl
e
1.
St
ud
ie
s
us
in
g
co
m
pu
te
d
to
m
og
ra
ph
y
to
as
se
ss
va
sc
ul
ar
ca
lc
ifi
ca
ti
on
in
pa
ti
en
ts
w
it
h
ki
dn
ey
di
se
as
e
(s
ee
)
A
ut
ho
rs
D
es
ig
n
Po
pu
la
ti
on
Im
ag
in
g
m
od
al
it
y
V
as
cu
la
r
B
ed
P
T
X
C
a
P
O
4
tr
ea
tm
en
t
C
A
C
de
te
rm
in
an
ts
B
ra
un
C
C
49
E
SR
D
-H
D
H
ig
h-
re
so
lu
ti
on
C
T
C
or
on
ar
y
N
D
P
O
4
bi
nd
er
s
(N
D
)
C
A
C
sc
or
e
re
la
te
d
to
ag
e,
hy
pe
rt
en
si
on
,n
ot
C
,P
,P
T
H
,o
r
V
D
A
19
96
[5
]
N
=
15
1
10
2
C
A
D
co
nt
ro
ls
C
ar
di
ac
va
lv
es
V
D
A
A
ge
=
55
M
en
=
69
%
T
im
e
pe
ri
od
12
m
on
th
s
G
oo
dm
an
20
00
[2
4]
C
C
39
E
SR
D
E
B
C
T
C
or
on
ar
y
P
T
X
in
23
%
O
ra
lc
al
ci
um
(N
D
)
C
A
C
re
la
te
d
to
ag
e,
D
V
,b
od
y
m
as
s
in
de
x,
C
P
P,
al
bu
m
in
,c
ho
l,
do
se
C
a/
da
y,
no
tC
,P
,o
r
P
T
H
N
=
99
(1
8-
H
D
A
ge
=
19
21
-C
A
P
D
)
M
en
=
49
%
60
H
ea
lt
hy
co
nt
ro
ls
C
he
rt
ow
20
02
[3
8]
P
C
(R
C
T
)
E
SR
D
-H
D
E
B
C
T
C
or
on
ar
y
N
D
C
al
ci
um
ca
rb
on
at
e
or
ca
lc
iu
m
ac
et
at
e
vs
.s
ev
el
am
er
Se
ve
la
m
er
w
it
h
re
du
ce
d
L
D
L
-C
as
so
ci
at
ed
w
it
h
at
te
nu
at
io
n
of
pr
og
re
ss
io
n
of
C
A
C
.N
o
di
ff
er
en
ce
in
C
P
P
or
P
T
H
N
=
20
0
A
ge
=
56
M
en
=
64
%
Fo
llo
w
-u
p
=
12
m
on
th
s
O
h
20
02
[4
3]
C
S
13
E
SR
D
-H
D
E
B
C
T
C
or
on
ar
y
N
D
N
D
C
A
C
re
la
te
d
to
hs
-C
R
P,
P
T
H
,C
P
P,
ho
m
oc
ys
te
in
e
N
=
39
26
R
T
R
U
S
C
ar
ot
id
IM
T
re
la
te
d
to
D
V
,C
,P
,C
P
P,
no
tP
T
H
A
ge
=
72
39
H
ea
lt
hy
co
nt
ro
ls
Se
x
N
D
O
ku
da
20
02
[4
4]
C
C
22
1
E
SR
D
E
B
C
T
A
or
ta
N
D
N
D
A
o
ca
lc
.r
el
at
ed
to
ag
e,
D
V
,n
ot
C
,P
,
C
P
P
N
=
66
3
44
2
H
ea
lt
hy
co
nt
ro
ls
A
ge
=
55
M
en
=
63
%
R
ag
gi
20
02
[4
5]
C
S
E
SR
D
-H
D
E
B
C
T
C
or
on
ar
y
ao
rt
ic
ca
rd
ia
c
va
lv
es
P
T
X
in
7%
C
al
ci
um
ca
rb
on
at
e
ca
lc
iu
m
ac
et
at
e
se
ve
la
m
er
C
A
C
re
la
te
d
to
ag
e,
fe
m
al
e
ge
nd
er
,
di
ab
et
es
,D
V
,C
,P
,n
ot
C
P
P,
P
T
H
N
=
20
5
A
o
ca
lc
.r
el
at
ed
to
ag
e,
bl
ac
k
ra
ce
,
D
V
,n
ot
re
la
te
d
to
C
,P
,C
P
P,
P
T
H
A
ge
=
57
M
en
=
64
%
M
oe
20
02
[4
6]
C
S
E
SR
D
P
at
ho
lo
gi
c
ex
am
E
pi
ga
st
ri
c
N
D
O
ra
lc
al
ci
um
(N
D
)
E
pi
ga
st
ic
ar
te
ry
ca
lc
.r
el
at
ed
to
D
M
,
P,
C
,C
P
P,
pe
ri
to
ne
al
di
al
ys
is
N
=
41
25
-H
D
C
T
of
sp
ec
im
en
V
D
A
in
64
%
A
ge
=
45
14
-P
D
M
en
=
76
%
2-
no
td
ia
ly
ze
d
go
in
g
fo
r
re
na
lt
ra
ns
pl
an
t
N
it
ta
20
01
[4
7]
C
C
36
C
T
A
or
ta
N
D
N
D
A
o
ca
lc
.r
el
at
ed
to
os
te
op
on
ti
n
le
ve
ls
,
no
tC
,P
,P
T
H
N
=
71
E
SR
D
-H
D
A
ge
=
54
35
he
al
th
y
co
nt
ro
ls
M
en
=
54
%
S-22 McCullough and Soman: Cardiovascular calcification in chronic renal failure
Ta
bl
e
1.
(C
on
tin
ue
d)
Im
ag
in
g
C
a
P
O
4
A
ut
ho
rs
D
es
ig
n
Po
pu
la
ti
on
m
od
al
it
y
V
as
cu
la
r
B
ed
P
T
X
tr
ea
tm
en
t
C
A
C
de
te
rm
in
an
ts
Ta
m
as
hi
ro
20
01
[4
8]
P
C
E
SR
D
-H
D
C
T
C
or
on
ar
y
N
o
N
D
C
A
C
pr
og
re
ss
io
n
re
la
te
d
to
T
C
,H
D
L
-C
,n
ot
C
,
P,
P
T
H
N
=
24
P
T
X
A
ge
=
53
M
en
=
53
%
T
im
e
po
in
ts
17
m
on
th
s
M
oe
20
03
[4
9]
P
C
N
=
38
R
T
X
Sp
ir
al
C
T
C
or
on
ar
y
ao
rt
a
N
o
N
D
C
A
C
re
la
te
d
to
ag
e
an
d
D
V
N
=
71
N
=
33
E
SR
D
-H
D
P
T
X
M
at
su
ok
a
20
04
[4
1]
P
C
E
SR
D
-H
D
E
B
C
T
C
or
on
ar
y
N
o
N
D
C
A
C
ra
ng
e
0
to
58
96
,m
ed
ia
n
of
20
0
N
=
10
4
P
T
X
C
A
C
>
20
0
in
de
pe
nd
en
tl
y
re
la
te
d
to
al
l-
ca
us
e
m
or
ta
lit
y
A
ge
=
56
Fo
llo
w
-u
p
44
m
on
th
s
A
bb
re
vi
at
io
ns
ar
e:
A
o,
ao
rt
a;
A
V
C
,a
or
ti
c
va
lv
e
ca
lc
ifi
ca
ti
on
;C
A
C
,c
or
on
ar
y
ar
te
ry
ca
lc
ifi
ca
ti
on
;C
C
,c
as
e
co
nt
ro
l;
C
H
O
L
,t
ot
al
ch
ol
es
te
ro
l;
C
P
P,
ca
lc
iu
m
-p
ho
sp
ho
ru
s
pr
od
uc
t;
C
S,
cr
os
s-
se
ct
io
na
l;
C
T,
co
m
pu
te
d
to
m
og
ra
ph
y
(i
nc
lu
de
s
el
ec
tr
on
-b
ea
m
);
C
V
D
,c
ar
di
ov
as
cu
la
r
di
se
as
e;
D
V
,d
ia
ly
si
s
vi
nt
ag
e
(d
ur
at
io
n
in
ye
ar
s)
;E
SR
D
,e
nd
-s
ta
ge
re
na
ld
is
ea
se
;E
SR
D
-H
D
,e
nd
-s
ta
ge
re
na
ld
is
ea
se
on
he
m
od
ia
ly
si
s;
H
D
L
-C
,h
ig
h-
de
ns
it
y
lip
op
ro
te
in
ch
ol
es
te
ro
l;
hs
-C
R
P,
hi
gh
se
ns
it
iv
it
y
C
-r
ea
ct
iv
e
pr
ot
ei
n;
IM
T,
in
ti
m
al
m
ed
ia
lt
hi
ck
ne
ss
;M
A
C
,m
it
ra
la
nn
ul
ar
ca
lc
ifi
ca
ti
on
;M
C
C
,m
yo
ca
rd
ia
lc
al
ci
um
co
nt
en
t;
O
P
N
,o
st
eo
po
nt
in
;P
C
,p
ro
sp
ec
ti
ve
co
ho
rt
;P
T
H
,
pa
ra
th
yr
oi
d
ho
rm
on
e;
P
T
X
,p
ar
at
hy
ro
id
ec
to
m
y;
P
W
V
,p
ul
se
w
av
e
ve
lo
ci
ty
;R
C
T,
ra
nd
om
iz
ed
co
nt
ro
lle
d
tr
ia
l;
R
T
R
,r
en
al
tr
an
sp
la
nt
re
ci
pi
en
t;
T
G
,t
ri
gl
yc
er
id
es
;V
D
A
,v
it
am
in
D
an
al
og
ue
s;
N
D
,n
ot
do
cu
m
en
te
d.
function and malfunction were not reported. The mean
and median DV times were 14 and 13 versus 4 and
2 years for those with and without CAC, respectively
(P < 0.0001). In contrast, the CPP values were 65 and 56
for those with and without CAC, respectively (P = 0.04).
In the Treat to Goal trial by Chertow et al, 200 subjects
were randomized to sevelamer versus calcium carbonate
(in Europe) or calcium acetate (in the United States),
and had EBCT scans done at baseline and at 52 weeks
[39]. Investigators were not blinded to the measures of
Ca-PO4 balance and were allowed to adjust phosphate-
binders, dialysate calcium, or use VDA. The baseline and
final CPP values were 71 and 48 (difference 23), and 69
and 49 (difference 20); for the sevelamer and calcium
groups, respectively. However, there was a large differ-
ence in the final LDL-C levels between the sevelamer
and the calcium groups; 65 versus 103 mg/dL, respectively
(P < 0.0001). This is consistent with the known bile-acid
sequestrant properties of sevelamer. Accordingly, there
was attenuation of progression of CAC with sevelamer
with no differences in CPP or PTH, suggesting the change
in CAC was more related to lipid lowering, as has been
demonstrated in other studies [39].
Coronary calcification found on cineangiography dur-
ing a diagnostic catheterization has been associated with
smaller lumen diameters. However, Bonifacio [36] re-
ported in patients with ESRD that after these calcified
lesions were dilated they had a lower rate of cardiac
events and a prolonged survival. Coronary calcification
in this study was associated with a lower total cholesterol
level, despite equal rates of lipid-lowering therapy and
CPP in those with and without calcification. This needs
to be viewed in the setting of malnutrition as a function
of dialysis vintage and the possibility of lower levels of
cholesterol on that basis.
Eight analyses have determined a relationship between
CAC and measure of calcium-phosphate balance, while
20 analyses specifically did not find such a relationship
[38]. Three studies have suggested the degree of cal-
cium loading, treatment with phosphate binders, or treat-
ment with vitamin D analogues were related to CAC
[38]. When taken into consideration, the lipid profile (pri-
marily low high-density lipoprotein cholesterol, elevated
triglycerides, elevated low-density lipoprotein, and ele-
vated total cholesterol) were predictive factors in four
analyses. Most studies were too small for valid multivari-
ate analyses, but five studies did use various techniques in
an attempt to identify the independent predictors. When
this was done measures of Ca-PO4, in general, either
dropped out of the model or markedly attenuated as pre-
dictive factors. Conversely, age, DV, and lipid parameters
retained independent predictive value for the outcome
of CAC or the progression of CAC.
A recent study in ESRD patients on dialysis demon-
strated that there is no significant positive correlation
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Fig. 4. Stabilizing effect of vascular calcification in aortic atheroscle-
rosis on the outcome of future vascular events (stroke, retinal artery oc-
clusion, myocardial infarction, peripheral embolism, bowel infarction,
and death from a vascular cause, including sudden death). Reproduced
with permission from reference [52].
between the severity of CAC measured by EBCT and the
degree of occlusive CAD [40]. However, the total absence
of any CAC strongly correlated with the absence of sig-
nificant atherosclerotic disease. Although the numbers of
patients examined were small, the study was powered to
detect a significant correlation between individual artery
calcification score and plaque burden (power = 0.93,
N = 52 vessels) [40].
Unfortunately, most studies did not provide follow-up
for specific cardiovascular outcomes. However, a recent
study has linked CAC to all-cause mortality in ESRD [41–
42]. It is unknown, at the very high levels of CAC seen
in ESRD, whether the absolute CAC score is related to
increased or perhaps decreased CAD risk. How could a
high CAC mediate reduced CAD risk? It is believed that
coronary atherosclerosis undergoes a natural history, and
that at the very late stages of atherosclerosis the plaque
is relatively lipid-depleted, fibrous, and heavily calcified
[26]. Interestingly, a recent study of patients with aor-
tic atherosclerosis found that calcification determined by
transesophageal echocardiography was associated with
a lower rate of embolic events (see Fig. 4) [52]. So is a
heavily calcified lesion more or less likely to rupture in
the future? The answer is currently unknown. This is the
crux of the argument concerning the value and meaning
of CAC in ESRD. Does attenuation of the progression of
CAC in ESRD patients, when the score is already at high
levels, reduce the chances of a CAD event attributed to
a calcified lesion? This will be difficult to answer because
the therapies (statins and sevelamer) that reduce attenu-
ation of progression do so by primarily reducing LDL-C
and likely stabilizing less severe plaques elsewhere in the
coronary bed.
CONCLUSION
CAC is a common observation in CKD and ESRD, and
is mainly related to age, duration on dialysis, and possibly
dyslipidemia. The calcium-phosphorus balance and its as-
sociated treatments are likely not related to this unique
form of vascular calcification. In fact, most analyses so far
specifically demonstrate that calcium, phosphorus, CPP,
and PTH levels, whether measured in cross-section or
longitudinally, are not related to CAC or its progression.
However, clearly more work needs to be done to fully
elucidate the role of calcium-phosphorus dysregulation
in the initiation and/or maintenance of CAC in ESRD.
While high levels of CAC almost certainly represent sig-
nificant CAD in patients with ESRD, the attenuation of
progression of CAC and its relation, if any, to CAD event
reduction is unknown. At the time of this writing, CAC
by EBCT does not have enough evidence to be a sur-
rogate marker for CAD event risk reduction in patients
with CKD or ESRD.
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